Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines (Q46547178)

23 December 2017

title

Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines (English)

1 reference

23 December 2017

0 references

1 reference

Weiya Z Wysham

1

1 reference

23 December 2017

Dario R Roque

2

1 reference

23 December 2017

Jianjun Han

3

1 reference

23 December 2017

Lu Zhang

4

1 reference

23 December 2017

Hui Guo

5

1 reference

23 December 2017

Paola A Gehrig

6

1 reference

23 December 2017

Chunxiao Zhou

7

1 reference

23 December 2017

Victoria L Bae-Jump

8

1 reference

23 December 2017

publication date

18 May 2016

1 reference

23 December 2017

published in

Targeted oncology

1 reference

23 December 2017

volume

11

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

page(s)

763-769

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1007/s11523-016-0442-9

exact match

0 references

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Factors associated with Type I and Type II endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Orlistat, a new lipase inhibitor for the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Fatty acid synthase: a metabolic oncogene in prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Fatty acid synthase as a potential therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Obesity induced rapid melanoma progression is reversed by orlistat treatment and dietary intervention: role of adipokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Lipid catabolism via CPT1 as a therapeutic target for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Targeting AMPK: a new therapeutic opportunity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0442-9

Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker.

21 January 2018

1 reference

12 December 2020

Fatty acid synthesis is a therapeutic target in human liposarcoma

1 reference

12 December 2020

The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells

1 reference

12 December 2020

Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.

1 reference

12 December 2020

The impact of obesity and age on quality of life in gynecologic surgery

1 reference

12 December 2020

Fatty acid synthase expression and clinicopathological findings in endometrial cancer

1 reference

12 December 2020

Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules

1 reference

12 December 2020

Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death.

1 reference

12 December 2020

10.1007/S11523-016-0442-9

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

27188391

1 reference

23 December 2017